Pre-pubertal growth in the hyperprostaglandin E syndrome.
Pre-pubertal body growth was followed in eight children with the hyperprostaglandin E syndrome (neonatal Bartter syndrome) treated with indomethacin over a period of 5-12 years. When corrected for prematurity, the general growth pattern was normal, with the exception of a child with delayed therapy. From the first observation (usually at birth) to the start of indomethacin, the mean height standard deviation score (SDS) corrected for prematurity changed from -0.2 to -2.8. During the first 2 years of therapy rapid catch-up growth occurred, followed by a slow adaptation of the growth pattern to that of healthy children born at term. At last observation the mean corrected height SDS was -0.5 (range -1.9 to +0.9) and the mean target height -0.9 SDS (range -1.8 to +0.1). Weight, body mass index and bone maturation also reached the normal range. No correlation was found between height SDS per year and serum potassium levels or calcium excretion. We conclude that under indomethacin treatment long-term skeletal growth of children with the hyperprostaglandin E syndrome is similar to that of other preterm children.
Seidel
C
C
University Children's Hospital, Heidelberg, Germany.
Reinalter
S
S
Seyberth
H W
HW
Schärer
K
K
D001477:Bartter Syndrome / Q000188:drug therapy / Q000503:physiopathology*; D002118:Calcium / Q000652:urine; D002648:Child; D002675:Child, Preschool; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D015232:Dinoprostone / Q000652:urine; D005260:Female; D006128:Growth / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D011188:Potassium / Q000097:blood; D011458:Prostaglandins E / Q000097:blood* / Q000652:urine; D011627:Puberty
D016861:Cyclooxygenase Inhibitors; D011458:Prostaglandins E; D015232:Dinoprostone; D011188:Potassium; D002118:Calcium; D007213:Indomethacin